Sunesis Reports Financial Results for the Second Quarter 2009

... and efficacy in AML and in platinum-resistant ovarian cancer. These presentations can be found on the ... agent voreloxin in women with platinum-resistant ovarian cancer were also presented at the ASCO 2009 ... Phase 2 single-agent trial in platinum-resistant ovarian cancer. About Acute Myeloid Leukemia ...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

... pregnancy rates in women undergoing controlled ovarian stimulation (COS) with a standardized rFSH / ... weight categories. It showed that exposure and ovarian response were similar after a single-dose of 100 ... development during the first week of ovarian stimulation.(6) About ENGAGE ENGAGE was a ...

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

... PSA levels in prostate cancer or CA-125 levels in ovarian cancer were also observed. A reduction in PSA ... levels was observed in 3 of 5 patients (60%) with ovarian cancer. "CTCs are emerging as an exciting ... and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III ... (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the OVA-301 ... of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study ...

Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement

... Commitment to the Development of Farletuzumab for ovarian Cancer Agreement Highlights Lonza's Ability ... recently entered Phase III clinical trials for ovarian cancer under a Special Protocol Assessment (SPA) ... bringing a new treatment option for patients with ovarian cancer. About Lonza Lonza is one of the ...

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

... patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer." ... designation for ENMD-2076 for the treatment of ovarian cancer. Several ovarian cancer patients participated in the ENMD-2076 ...

ASCP Joins ACLU Lawsuit Opposing Gene Patents

... BRCA2 genes, which are associated with breast and ovarian cancer. The lawsuit was filed against the U.S. ... BRCA2 genes, which are associated with breast and ovarian cancer. The lawsuit (Case 1:09-cv-04515-RWS ... the person is at a higher risk of breast and/or ovarian cancer. Women who fear they may be at an ...

BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management

... to First Develop Powerful Tools for Detecting ovarian Cancer Earlier FRANKLIN LAKES, N.J. and ... The initial products will be directed to the ovarian cancer biomarker, HE4, which is FDA-cleared for ... the progression or recurrence of epithelial ovarian cancer. Fujirebio Diagnostics also grants BD, ...

NFGC Conducts Multi-Institutional Research Project in Ovarian Cancer

... a multi-institutional collaborative project in ovarian cancer. For the first phase of the project, ... mutations in preclinical models by profiling ovarian cancer cells and ovarian cancer stem cells. The consortium will also ...

Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting

... phase 2 monotherapy clinical study in recurrent ovarian cancer. The study reported in the 2009 AACR ... phase 2 clinical study in patients with recurrent ovarian cancer, and from in vitro data reported ... in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of ...

Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code

... regulatory clearance respecting the company's ovarian tumor triage test ("OVA1") 510(k) pre-market ... About OVA1 Vermillion has multiple ovarian cancer diagnostic tests in development. The most ... women who were scheduled for surgery with an ovarian mass. The data demonstrated that the OvaCalc ...

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results

... of single-agent voreloxin in platinum-resistant ovarian cancer patients at the 12th Biennial Meeting ... Phase 2 single-agent trial in platinum-resistant ovarian cancer. About Acute Myeloid Leukemia ... need for new treatment options. About ovarian Cancer In the United ...

AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results

... AEZS-108 for a Phase 2 trial in advanced ovarian and endometrial cancers. - March - ... for AEZS-108 Phase 2 trial in advanced ovarian and endometrial cancers. - December - ... oncology compound, AEZS-108, in endometrial and ovarian cancer with results expected by the end of this ...

Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer

... Assay to Improve Diagnosis and Treatment of ovarian Cancer - FREMONT, Calif., Feb. 12 ... for the discovery of hepcidin as a biomarker for ovarian cancer. The discovery could ultimately lead to ... with additional, valuable information to diagnose ovarian cancer. "The notice of issuance of this ...

Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin

... 2 trials for acute myeloid leukemia (AML) and ovarian cancer. The clinical update coincides with the ... the development of voreloxin in both AML and ovarian cancer. We believe voreloxin has the potential ... enrollment of our Phase 2 platinum-resistant ovarian cancer study and both of our ongoing AML studies ...

Interim Report for the Period 1 January - 30 September 2008 (Unaudited)

... initiated. These results are important to ovarian cancer treating physicians since ovarian cancer ... clinical trial on 719 late stage epithelial ovarian cancer patients conducted by The European ... for response to first-line treatment in advanced ovarian cancer patients. Financial outlook 2008 ...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

... treat up to 82 women with LHRH-receptor positive ovarian and endometrial cancerous tumors. The primary ... compound, AEZS-108 in both endometrial and ovarian cancer. The data also strengthens our belief that ... (up to 41 with a diagnosis of platinum-resistant ovarian cancer and up to 41 with disseminated endometrial ...

Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer

... resistant or secondary platinum resistant ovarian cancer (definitions of platinum status ... well-balanced for patient demographics and key ovarian cancer disease characteristics. Telcyta ... About Platinum Refractory and Resistant ovarian Cancer Platinum refractory or primary ...

Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer

... clinical trial on 719 late stage epithelial ovarian cancer patients (named 55971). Results were ... for response to first-line treatment in advanced ovarian cancer patients. The clinical trial results ... is initiated. These results are important to ovarian cancer treating physicians ...

Ferring Celebrates Winner of 2008 My Little Miracle Essay Contest During National Infertility Awareness Week

... and BRAVELLE are not indicated in women with ovarian failure, uncontrolled thyroid and adrenal ... mild to severe adverse reactions, including ovarian Hyper Stimulation Syndrome (OHSS), with or ... these medications. Like other products for ovarian stimulation, treatment with MENOPUR and/or ...

Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options

... ("CO-eXpression ExtrapolatioN"). ovarian cancers are often diagnosed at the advanced stage ... believe physicians will be able to quickly direct ovarian cancer patients towards appropriate lines ... frequent cause of cancer death in women. In 2008, ovarian cancer will be diagnosed in more than 20,000 ...

Abeome Forms First Class Scientific Advisory Board

... to collaborate on the development of Abeome's ovarian cancer project and to select and guide future ... and to participate in target validation on our ovarian cancer therapeutic project. Their active ... and clinical trials, unparalleled knowledge of ovarian cancer pathology, and years of ...

National Ovarian Cancer Coalition and PureOlogy to Host First Annual 'NOCC and PureOlogy's Walk to Break the Silence on Ovarian Cancer'

... Host to Help Educate Women Nationwide About ovarian Cancer - LOS ANGELES, Sept. 6 /PRNewswire/ -- Today the National ovarian Cancer Coalition (NOCC) and PureOlogy, its ... and PureOlogy's Walk to Break the Silence on ovarian Cancer" at Dockweiler Beach in Playa del Ray, CA. ...

33rd ESMO Congress in Stockholm, 12-16 September 2008

... from Flinders University in Australia. ovarian Cancer Drug shows promise in ovarian cancer (Embargoed until Monday, 15 September ... CEST) An investigational drug that combats ovarian cancer by inhibiting the formation of new blood ...

Rosetta Genomics Reports Second Quarter 2008 Financial Results

... These tests are focused on predicting response to ovarian cancer treatment, predicting risk of gastric ... - Predicting response to treatment of ovarian cancer patients - Platinum-based cytotoxic ... gold standard of treatment for patients with ovarian cancer. However, approximately 20-25% of patients ...

Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission

... keynote speaker of the roundtable. Vermillion's ovarian tumor triage test utilizes a panel of ... tumors are benign, studies show that women with ovarian cancer have improved median and overall ... by a gynecologic oncologist. About Vermillion's ovarian Cancer Diagnostic Program In addition to ...

Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development

... Programs to Include Response Prediction to ovarian Cancer Treatment, Predicting Risk of Gastric ... 1) Predicting response to treatment of ovarian cancer patients - Platinum-based cytotoxic ... biomarkers that may assist in identifying ovarian cancer patients expected to benefit from ...

Vermillion Announces First Quarter 2008 Financial Results and Business Progress

... future clinical use of VASCLIR. -- ovarian Cancer Diagnostic Program * Continued to ... the benefits of the Company's ovarian cancer diagnostic test programs at the ... could help better identify women with early-stage ovarian cancer and improve detection. * ...

Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer

... their prescribing decisions in advanced ovarian cancer. Clinical data and expert opinion show ... the current sales leader in ovarian cancer treatment. The new report entitled ovarian Cancer (Advanced): Therapies Must Increase ...

FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research

... data on FAS31, FASgen's lead compound for ovarian cancer. FAS31 is an inhibitor of fatty acid ... inhibits fatty acid synthesis in SKOV3 human ovarian cancer cells in vitro (IC-50 = 6.09 +/- 0.4 ... successful mouse efficacy trials in human ovarian cancer cell lines, showing 80% reduction in ...

Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones

... programs for peripheral artery disease (PAD), ovarian cancer and thrombotic thrombocytopenic purpura ... of 2008, Vermillion has advanced its PAD and ovarian cancer diagnostic programs, as well as ... exclusive rights to the biomarker panel. ovarian Cancer Diagnostic Test Progress -- Received the ...

AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers

... treat up to 82 women with LHRH-receptor positive ovarian and endometrial cancerous tumors. The primary ... (up to 41 with a diagnosis of platinum-resistant ovarian cancer and up to 41 with disseminated endometrial ... agents in inhibiting tumor growth. About ovarian and endometrial cancer ...

Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Women's Biological Clock

... Test Offers Most Accurate Measurement of Women's ovarian Reserve ATLANTA, ... Dr. Perloe. "And while we know that on average ovarian reserve begins a more rapid decline after age 35, ... women with the individual assessment of their own ovarian reserve to help them make more informed decisions ...

Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

... lead candidate, SNS-595, in platinum-resistant ovarian cancer will be featured in a poster session on ... in women with platinum refractory epithelial ovarian cancer * Poster Session A -Small Molecule ... 1b acute leukemia clinical trials and a Phase 2 ovarian cancer clinical trial. SNS-032, Sunesis' ...

ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens

... discovery company. These proprietary antigens specifically target breast, ovarian and prostate cancers. IVT will combine the proprietary antigens with its ... DPX-0907 into Phase 1 clinical trials. "Advanced-stage breast, ovarian and prostate cancers remain devastating and challenging diseases that ...

New Report Just Published: World Endoscopy Systems Market Report

... II-31 Obstetric/Gynecology II-32 Fallopian & ovarian Laparoscopy II-32 Endometriosis II-32 Tubal Ligation II-32 Vagina Creation II-32 Laparoscopic Myomectomies II-32 ovarian Cystectomy II-33 Female Infertility II-33 Female Sterilization ...

Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C

... exclusive national reference laboratory provider of the blood-based HE4 ovarian Cancer Monitoring test, which is FDA-cleared as an aid in monitoring epithelial ovarian cancer. The company is also developing a molecular blood test based on ...

Groundbreaking Research Begins for Pancreatic and Lung Cancers

... from the acclaimed work of Dr. McDonald and Benedict Beningo, MD, with ovarian cancer patients, the current research is the first to focus on pancreatic ... to be the most fatal of common cancers. Pancreatic cancer is similar to ovarian cancer in that it often goes undetected until the disease is too far ...

Cynvec to Present at the BIO National Venture Conference

... and highly significant survival rates in pre-clinical models of ovarian and pancreatic cancer as both a single agent and in combination with ... diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in ovarian cancer in the third quarter of 2009. The sindbis vector has also ...

Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial

... with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to standard therapy or ... Gemzar(R) is indicated for NSCLC, breast, pancreatic and ovarian cancer. For more information about Gemzar(R), please visit www.gemzar.com ...